MONTREAL, QUEBEC ("Mistral") today announced positive results from a first pilot pharmacokinetic (PK) study on a new controlled-release product, MIST-B04. The results of this pilot study clearly show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation presently on the market. MIST-B04 is formulated using a new drug delivery platform named TRIZERO(TM), which was developed internally by Mistral's scientists and for which a patent application was filed in June 2007.

"We are very excited by these positive results on MIST-B04" commented Bertrand Bolduc. "They show that our brand new TRIZERO(TM) platform is performing very well in vivo and this opens up many other opportunities for line-extension products for MIST-B04" he added.

Mistral's MIST-B04 is a controlled-delivery branded product in the rheumatology / inflammation field. According to Drug Topics, sales for the branded product targeted by MIST-B04 were more than US$ 200 M in the US in 2006.

About Mistral Pharma Inc.

Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive results at their respective first pilot clinical trials. Mistral also markets INSTILLAGEL� in Canada, a local anesthetic and antiseptic combination product used for urology procedures. Mistral has also in-licensed TAMALIS(TM) (Rupatadine) a new antihistamine and INSTILLAQUILL�, a single use extension tube used in gynecology. They should both be filed with Health Canada in 2008. Mistral positions itself as a development and marketing partner for pharmaceutical companies. More information is available on Mistral's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA President & Chief Executive Officer 514-421-1717 # 2224 bbolduc@mistralpharma.com Mistral Pharma Inc. Alain Provencher, CA, CF Vice-president, Finance & Chief Financial Officer 514-421-1717 # 2222 aprovencher@mistralpharma.com

Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Mistral Pharma
Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Mistral Pharma